RA Williams returns to profit in Q3
Profit for pharmaceutical distributor RA Williams Limited rebounded during the third quarter ended January 31, 2026, after the company moved decisively to address operational challenges that weighed on its performance in previous quarters.
During the third quarter, net profit — after almost doubling when compared year on year — grew to $33.5 million, marking a 136 per cent increase. This was earned on the back of stronger revenues which totalled $541.9 million or a 23 per cent increase.
The return of profitability for the company marked a sharp turnaround following macroeconomic pressures and weather-related disruptions experienced during previous quarters when the business was pushed into losses.
“After the pressures we faced last quarter, we focused on strengthening our operations, controlling costs and ensuring that our products remained consistently available across the island,” CEO Audley Reid said.
“By keeping a close eye on our resources and supporting our teams on the ground, we were able to recover quickly. These efforts have allowed us to return to strong growth while continuing to provide reliable service to our customers,” he added.
The company’s previous challenges, exacerbated by the passage of Hurricane Melissa, which struck Jamaica as a Category 5 system last October, further pushed the company’s ailing bottom line in the red as business closures and damage sustained by clients in some of its key generating areas across western parishes sent profit growth into a tailspin.
For the second quarter ended October 31, 2025, RA Williams recorded a net loss of $26.8 million, building on the $1.9-million loss it registered for the first quarter ended July 31, 2025.
Touting the combination of healthy revenue growth and enhanced operational efficiency as part of the strategy that helped to reverse the company’s previous misfortunes, Reid further said this enabled the company to record an operating profit of $52.87 million for the quarter, also near doubling the $28.58 million achieved in the same period last year.
“A major highlight of the quarter was the tangible result of management’s active drive to improve cost control, a core focus outlined at the close of the second quarter,” the company’s directors noted in the third-quarter report to shareholders.
Cost management played a central role in the improved performance as total operating expenses declined to $162.3 million, down from $175.5 million in the same period last year. The reduction was largely driven by lower administrative and general expenses, which fell from $114.6 million to $98.7 million.
For the reporting period, the company also strengthened its balance sheet as total assets increased to $1.63 billion, while shareholders’ equity rose to $774.9 million, as management retained earnings and continued investment in operations to support growth in pharmaceutical distribution.
Founded in 2012 by pharmacists, RA Williams is a junior market-listed company that supplies a wide range of prescription and over-the-counter medications to pharmacies and health-care providers across Jamaica. The company is currently awaiting regulatory approval for several additional therapies as it prepares to expand its product offerings and regional footprint.
The company’s board, expressing confidence in its long-term strategy, said that targeted investments made during the first half of the year in brand visibility, infrastructure, and expanding our product portfolio, such as our entry into new therapeutic and wellness categories, are now delivering measurable results.
“As we progress into the final quarter of the financial year, management will continue to prioritise long-term revenue growth, careful management of trade partnerships, and deepened engagement with health-care professionals across Jamaica,” directors said in the report.
“Profitability is only meaningful when it supports long-term impact, and as such, we are reinvesting in our operations while deepening engagement with our partners to ensure that our growth benefits shareholders and the wider health-care community alike,” Reid also said.